Effect of Posterior Nasal Nerve Ablation on Biomarker Expression in Patients With Chronic Rhinitis
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Objective: This study evaluated changes in inflammatory and neurogenic biomarkers in nasal secretions in relation to clinical outcomes following temperature-controlled radiofrequency (TCRF) posterior nasal nerve (PNN) ablation in patients with allergic (AR) and nonallergic (NAR) chronic rhinitis (CR). Methods: In this prospective multicenter study, 25 participants with moderate to severe CR underwent TCRF PNN ablation. Nasal secretions were collected at baseline and 3 months postprocedure and analyzed for inflammatory biomarkers (ECP, EGF, IFNγ, IgE, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17A, IL-17F, IL-22, IL-25, TNFα) and TRPV1, a sensory nerve marker. Reflective total nasal symptom scores (rTNSS) were assessed from baseline through 6 months. Results: Mean rTNSS decreased from 7.8 (95% CI: 7.0 to 8.7) at baseline to 4.3 (95% CI: 3.2 to 5.4) at 3 months, a 46% improvement; 75% of participants met responder criteria. Reductions were observed in TRPV1 (0.76-fold) and in epithelial derived IL-25 (0.89-fold) across AR and NAR patients. Reductions in IL-8 were associated with greater treatment response. Conclusions: TCRF PNN ablation was associated with symptom improvement in both AR and NAR patients with reduction in neurogenic and epithelial biomarkers, including TRPV1 and IL-25. These findings provide preliminary evidence that TCRF PNN ablation may be a neuroimmune modulatory therapy for CR. Level of Evidence: 3. Trial Registration: ClinicalTrials.gov (NCT06599736).
DOI: 10.1002/lio2.70628
Institutions: Thomas Jefferson University, University of Cincinnati
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,900
OpenAlex ID: W7236561940
